IMGN News and Press, ImmunoGen Inc. From 06/03/22

Update 12:15pm: Updates shares, adds other potential names benefitting from the deal. Blueprint Medicines (NASDAQ:BPMC) rose 4% after Bristol Myers (BMY) agreed to acquire Turning Point Therapeutics (TPTX) for over $4B in cash. Stifel said in a note that buy-rated Blueprint (BPMC) c...

Two Data Sets to be Presented at 2022 Annual Meeting Poster Highlighting Updated Data from SORAYA Characterizing Anti-Tumor Activity Selected for Best of ASCO ® Program: Tumor Reduction in 71.4% of Patients and Preliminary Median Overall Survival of 13.8 Months in Hig...

The clinical-stage biotech, ImmunoGen (NASDAQ:IMGN) announced on Monday that the US Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for its ovarian cancer therapy mirvetuximab soravtansine under priority review. With the BLA, ImmunoGen (IMGN) seeks FDA clea...

PDUFA Date is November 28, 2022 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has accepted and filed the Biologics License App...

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30 years, researchers have been looking into the potenti...

ImmunoGen is a promising turnaround equity that is approaching its inflection point in growth. Mirvetuximab is poised to gain approval toward yearend. In H2 this year, ImmunoGen is set to release a flurry of catalysts. For further details see: ImmunoGen: An Inflection Po...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will present at the upcoming H.C. Wainwright Global Investment Conference. The presentatio...

Image source: The Motley Fool. ImmunoGen (NASDAQ: IMGN) Q1 2022 Earnings Call May 06, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: ImmunoGen (IMGN) Q1 2022 Earnings Call Transcript

ImmunoGen, Inc. (IMGN) Q1 2022 Results Conference Call May 06, 2022 08:00 AM ET Company Participants Courtney O'Konek - Senior Director, Corporate Communications Mark Enyedy - President, CEO Anna Berkenblit - CMO Kristen Harrington-Smith - Chief Commercial Officer Susan Altschuller - CFO Conf...

ImmunoGen press release (NASDAQ:IMGN): Q1 GAAP EPS of -$0.10 beats by $0.11. Revenue of $38.08M (+142.5% Y/Y) beats by $17.24M. FY2022 outlook remains unchanged: Revenues between $75M and $85M vs. consensus of $84.98M; Operating expenses between $285Mand $295M; Cash and cash equivalents ...